EDWARDS TAVR RECEIVES FDA APPROVAL FOR PATIENTS WITH ASYMPTOMATIC SEVERE AORTIC STENOSIS
Transforming Care for Severe AS Patients
EDWARDS’ SAPIEN 3 ULTRA RESILIA VALVE DEMONSTRATES CONTINUED EXCELLENT OUTCOMES FOR PATIENTS IN REAL WORLD DATA
EDWARDS’ SAPIEN 3 ULTRA RESILIA VALVE DEMONSTRATES CONTINUED EXCELLENT OUTCOMES FOR PATIENTS IN REAL WORLD DATA
BD Completes Acquisition of Critical Care from Edwards Lifesciences
BD announced it has completed the acquisition of Edwards Lifesciences’ Critical Care product group, which will be renamed as BD Advanced Patient Monitoring.
FIRST ALL-FEMALE TAVI TRIAL SHOWS EXCELLENT OUTCOMES FOR WOMEN RECEIVING EDWARDS VALVES
Edwards Lifesciences announced the results from the RHEIA Trial.
FIVE-YEAR DATA SHOW EXCELLENT OUTCOMES FOR FEMALE AND SMALL ANNULUS PATIENTS WITH EDWARDS TAVR
FIVE-YEAR DATA SHOW EXCELLENT OUTCOMES FOR FEMALE AND SMALL ANNULUS PATIENTS WITH EDWARDS TAVR
Edwards Lifesciences to Sell Critical Care to BD
Agreement strengthens Edwards’ strategy to advance structural heart innovation.
LARGE, REAL-WORLD STUDIES DEMONSTRATE CONTINUED EXCELLENT OUTCOMES FOR PATIENTS RECEIVING EDWARDS SAPIEN TAVR
LARGE, REAL-WORLD STUDIES DEMONSTRATE CONTINUED EXCELLENT OUTCOMES FOR PATIENTS RECEIVING EDWARDS SAPIEN TAVR
Edwards’ EVOQUE Valve Replacement System First Transcatheter Therapy to Earn FDA Approval for Tricuspid Valve
Edwards’ EVOQUE Valve Replacement System First Transcatheter Therapy to Earn FDA Approval for Tricuspid Valve
Edwards receives CE mark for tricuspid valve replacement
The company expects to receive U.S. approval late next year.
EDWARDS LAUNCHES SAPIEN 3 ULTRA RESILIA VALVE FOLLOWING FDA APPROVAL
Edwards Lifesciences announced the launch of the SAPIEN 3 Ultra RESILIA valve, which incorporates Edwards’ breakthrough RESILIA tissue technology with the industry-leading SAPIEN 3 Ultra transcatheter aortic heart valve.
